Geovax Labs Inc - GOVXW STOCK NEWS

GeoVax Labs, Inc. (Nasdaq: GOVX) has appointed Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Prof. Lambe, a renowned vaccinology and immunology expert from the Oxford Vaccine Group, was a key figure in developing the Oxford/AstraZeneca COVID-19 vaccine. Her research focuses on designing vaccination strategies based on post-infection immune responses. GeoVax's Chief Scientific Officer, Dr. Mark Newman, highlighted how Prof. Lambe's expertise aligns with their vaccine and immunotherapy programs, including the recent BARDA Project NextGen Award for next-generation COVID-19 vaccines. David Dodd, GeoVax's Chairman and CEO, emphasized the importance of Prof. Lambe's insights for advancing their clinical trials and bringing new therapies to market.

GeoVax Labs, Inc. (Nasdaq: GOVX) reported its Q2 2024 financial results and provided a business update. Key highlights include:

1. Awarded BARDA Project NextGen (PNG) contract worth over $350 million to advance GEO-CM04S1, their next-generation COVID-19 vaccine, into a 10,000-participant Phase 2b study.

2. Partnered with Allucent, a global CRO, to conduct the Phase 2b trial.

3. Advancing Gedeptin® into an expanded Phase 2 clinical trial for first-recurrence head and neck cancer, with activation expected in H1 2025.

4. Produced first lot of GEO-CM04S1 with a commercial manufacturing platform.

5. Q2 2024 net loss of $5,064,042 ($1.99 per share), compared to $5,927,620 ($3.79 per share) in Q2 2023.

6. Cash balance of $1,561,712 as of June 30, 2024.

GeoVax Labs, Inc. (Nasdaq: GOVX) has announced plans for a Phase 2 trial of its Gedeptin® cancer therapy following a clinical advisory committee review. The trial will focus on first-recurrence head and neck cancer, combining Gedeptin with an immune checkpoint inhibitor. This decision comes after reviewing the completed PNP-002 Phase 1b/2a and PNP-001 Phase 1 trials, which demonstrated acceptable safety and efficacy in advanced head and neck squamous cell carcinoma (HNSCC) patients.

The planned Phase 2 trial aims to establish the efficacy of neoadjuvant Gedeptin therapy combined with an immune checkpoint inhibitor. It will involve approximately 6 patients, with pathologic response rate as the primary endpoint. GeoVax anticipates trial activation during the first half of 2025. The company is also pursuing development plans for Gedeptin in additional solid tumor indications in partnership with leading academic oncology centers.

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases, has announced it will release its second quarter 2024 financial results on Tuesday, August 6, 2024, after U.S. markets close. The company will host a live conference call and webcast at 4:30 p.m. ET on the same day to discuss the financial results and provide a corporate update.

Investors and interested parties can join the conference call using the following details:
- Domestic: (800) 715-9871
- International: +1 (646) 307-1963
- Conference ID: 3852178

A webcast of the call will be available at https://edge.media-server.com/mmc/p/qj3e68n8, with a replay accessible for three months after the event.

GeoVax Labs, Inc. (Nasdaq: GOVX) presented data on GEO-CM04S1, its next-generation Covid-19 vaccine candidate, at the 24th Annual World Vaccine Congress. The vaccine induces broadly specific antibody and T cell responses against SARS-CoV-2 variants, including Omicron XBB.1.5. Animal studies showed promising results in controlling disease and lung inflammation. Phase 2 clinical trials are anticipated to confirm these findings later this year.

GeoVax Labs, Inc. (Nasdaq: GOVX) announces Chief Scientific Officer, Mark Newman, PhD, to present data on GEO-CM04S1, the next-generation Covid-19 vaccine candidate, at the 24th Annual World Vaccine Congress. The presentation will highlight the vaccine's ability to induce broadly-specific antibody and T cell responses to combat SARS-CoV-2 variation.

GeoVax Labs, Inc. (Nasdaq: GOVX) announced that its Chairman and CEO, David Dodd, will present at the 36th Annual Roth Conference on March 18, 2024. The company will also host in-person investor meetings, providing a platform for institutional investors to engage with GeoVax leadership.

GeoVax Labs, Inc. achieves a milestone in developing a manufacturing process for Phase 3 and commercial production of MVA-based vaccines, including a next-generation Covid-19 vaccine. The company successfully transfers production to a commercial manufacturing platform, partnering with ABL Europe for cGMP manufacturing. GeoVax demonstrates progress in addressing medical needs for immunocompromised populations and enhancing manufacturing capabilities.

GeoVax Labs, Inc. (Nasdaq: GOVX) announced financial results and key operational achievements for 2023, focusing on progress in multiple clinical trials for their next-generation Covid-19 vaccine, GEO-CM04S1, and cancer therapy Gedeptin®. The company completed enrollment for Phase 2 trials of GEO-CM04S1, showcasing safety and efficacy against various SARS-CoV-2 strains. Results demonstrated potential protective immunity without the need for vaccine reconfiguration. Additionally, Phase 1/2 trial results for Gedeptin showed safety and tumor reduction, with plans for an expanded Phase 2 study. Operational developments included advancements in vaccine manufacturing processes and intellectual property achievements.